The present invention relates to the technical field of natural substance extraction. Disclosed is a method for extracting Citrulline from a watermelon. The method for extracting Citrulline from a watermelon in the present invention comprises Raw material pretreatment, ultrasound-enzymatic hydrolysis assisted solvent leaching, and purification steps. The purification step comprises microbial fermentation, ion-exchange resin purification, macroporous adsorption resin discoloration, and crystallization and recrystallization. The method for extracting Citrulline in the present invention is simple, requires a mild condition, and has a good extraction effect on Citrulline. The purity of Citrulline after purification is more than 90%. In addition, the Citrulline extracted by the method in the present invention meets the related health requirements and product quality standards, can be applied to food and health food industries as a raw material, and has natural security advantages.

The invention relates to substituted ureas, and compositions comprising the same, which in certain embodiments are useful for treating and/or preventing pain in a subject in need thereof.

The invention relates to substituted ureas, and compositions comprising the same, which in certain embodiments are useful for treating and/or preventing pain in a subject in need thereof.

Provided are processes for the preparation of (S)-tert-butyl 4,5-diamino-5-oxopentanoate, or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof. Also provided are solid forms of various intermediates and products obtained from the processes.

The present invention relates to the technical field of natural substance extraction. Disclosed is a method for extracting Citrulline from a watermelon. The method for extracting Citrulline from a watermelon in the present invention comprises Raw material pretreatment, ultrasound-enzymatic hydrolysis assisted solvent leaching, and purification steps. The purification step comprises microbial fermentation, ion-exchange resin purification, macroporous adsorption resin discoloration, and crystallization and recrystallization. The method for extracting Citrulline in the present invention is simple, requires a mild condition, and has a good extraction effect on Citrulline. The purity of Citrulline after purification is more than 90%. In addition, the Citrulline extracted by the method in the present invention meets the related health requirements and product quality standards, can be applied to food and health food industries as a raw material, and has natural security advantages.

The present invention provides a process of producing a trifluoromcthoxylated aryl or trifluoromothoxylated heteroaryl having the structure:

##STR00001## wherein A is an aryl or heteroaryl, each with or without substitution; and R.sub.1 is H, -(alkyl), -(alkenyl), -(alkynyl), -(aryl), -(heteroaryl), -(alkylaryl), -(alkylheteroaryl), NH-(alkyl), N(alkyl).sub.2, NH-(alkenyl), NH-(alkynyl) NH-(aryl), NH-(heteroaryl), O-(alkyl), O-(alkenyl), O-(alkynyl), O-(aryl), O-(heteroaryl), S-(alkyl), S-(alkenyl), S-(alkynyl), S-(aryl), or S-(heteroaryl), comprising: (a) reacting a compound having the structure:

##STR00002## with a trifluoromethylating agent in the presence of a base in a first suitable solvent under conditions to produce a compound having the structure:

##STR00003##

and (b) maintaining the compound produced in step (a) in a second suitable solvent under conditions sufficient to produce the trifluoromethoxylated aryl or trifluormethoxylated heteroaryl having the structure:

##STR00004##

A novel solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride (also referred to ATR-101) suitable for oral dosing, and to compositions, methods and kits relating thereto. ATR-101 has particular utility in the treatment of, for example, aberrant adrenocortical cellular activity, including adrenocortical carcinoma (ACC), congenital adrenal hyperplasia (CAH) and Cushing's syndrome.

Provided are processes for the preparation of (S)-tert-butyl 4,5-diamino-5-oxopentanoate, or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof. Also provided are solid forms of various intermediates and products obtained from the processes.

The invention relates to substituted ureas, and compositions comprising the same, which in certain embodiments are useful for treating and/or preventing pain in a subject in need thereof.

The invention relates to substituted ureas, and compositions comprising the same, which in certain embodiments are useful for treating and/or preventing pain in a subject in need thereof.